Abstract
Antagonists of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor are of considerable interest for various neurotherapeutic purposes, including preventing neuronal degeneration in stroke and CNS trauma, suppressing neuropathic pain and preventing the development of tolerance to opiate analgesics. Unfortunately, NMDA antagonists can cause potentially serious side effects, including acute neurodegenerative changes in corticolimbic regions of the adult rat brain and psychotic reactions in adult humans. We have been investigating the mechanisms underlying the neuropathological changes in rat brain and exploring methods of suppressing or preventing such changes. Here we report that α2 adrenergic agonists can prevent NMDA antagonist neurotoxicity. Therefore, administering α2 adrenergic agonists together with NMDA antagonists may be a valuable strategy for preventing adverse side effects of NMDA antagonists and making these agents safer for various neurotherapeutic purposes.
Similar content being viewed by others
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Farber, N., Foster, J., Duhan, N. et al. α2 Adrenergic Agonists Prevent MK-801 Neurotoxicity. Neuropsychopharmacol 12, 347–349 (1995). https://doi.org/10.1016/0893-133X(95)00048-I
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1016/0893-133X(95)00048-I
Keywords
This article is cited by
-
Prolonged ketamine infusion modulates limbic connectivity and induces sustained remission of treatment-resistant depression
Psychopharmacology (2021)
-
Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity
Molecular Psychiatry (2002)
-
Influence of flupirtine on a G-protein coupled inwardly rectifying potassium current in hippocampal neurones
British Journal of Pharmacology (1997)